|Podcasts|November 1, 2021
Addressing Implicit Bias in Oncology Nursing
Author(s)Lindsay Fischer
“It is not a ‘one and done kind of thing.” It is very important to implement these skills throughout the community. It's a practice. It's a behavioral change.”
Advertisement
For this episode of “The Vitals,” Oncology Nursing News spoke with Gretchen McNally, APRN-CNP, and Kathy Burns, MS, APRN-CNS, AGCNS-BC, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, on the importance of being mindful about one’s implicit bias in the treatment of patients with cancer who have substance use disorders.
Advertisement
Related to this article
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
Non-CME PER® Podcast
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinical trials and nursing impacts of on-body isatuximab delivery in multiple myeloma.
In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient end-stage hematology care.
Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events.
Real-time check-ins from patients with MBC showed quality of life dipped when depression, anxiety, or fatigue rose above usual levels.
FDA approves tucatinib maintenance with trastuzumab and pertuzumab for HER2+ breast cancer based on HER2CLIMB-05.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
IMS 2026: Beth Faiman Talks New Definition of Myeloma Cure and More
2
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer
3
Managing Oral and Ocular Toxicities in Metastatic Triple-Negative Breast Cancer
4
National PA Week: PA-Nurse Synergy Transforms Outpatient Hematology Care
5